Becker Sven
Universitätsklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie, Eberhard Karls Universität Tübingen, Elfriede-Aulhorn Str. 5, 72076, Tübingen, Deutschland.
HNO. 2025 Apr 16. doi: 10.1007/s00106-025-01635-y.
Chronic rhinosinusitis is one of the most common chronic diseases of the upper respiratory tract and is associated with a significant reduction in quality of life. Precise diagnostic workup is therefore necessary to provide patients with adequate treatment. The introduction of biologics has opened up new options for the treatment of severely affected patients with chronic rhinosinusitis with nasal polyps in the sense of precision medicine that goes beyond the mere control of symptoms. This has been accompanied by a certain degree of standardization with regard to diagnostic procedures and the assessment of disease-specific quality of life. Against the background of the 2025 congress theme "Individualization vs. standardization in otorhinolaryngology," this paper examines and summarizes the diagnosis and drug therapy of chronic rhinosinusitis, with a focus on biologic therapy.
慢性鼻-鼻窦炎是上呼吸道最常见的慢性疾病之一,与生活质量显著下降相关。因此,精确的诊断检查对于为患者提供充分治疗至关重要。生物制剂的引入为治疗患有鼻息肉的重度慢性鼻-鼻窦炎患者开辟了新的选择,这属于精准医学范畴,不仅仅是控制症状。同时,在诊断程序和疾病特异性生活质量评估方面也有了一定程度的标准化。在2025年大会主题“耳鼻咽喉科的个体化与标准化”的背景下,本文对慢性鼻-鼻窦炎的诊断和药物治疗进行了研究和总结,重点是生物治疗。